AstraZeneca Crestor Myopathy Seen At Lower Doses; EU Label Approved
Executive Summary
AstraZeneca's Crestor myopathy incidence in 40 mg and lower is less than .01%, Cardiovascular Therapy Head Hamish Cameron, MD, said during the company's annual business review Nov. 7
You may also be interested in...
AstraZeneca Crestor, Exanta Promotions Will Focus On Dosing Advantages
One of AstraZeneca's promotional messages for its statin Crestor (rosuvastatin) will likely focus on the ability of the 10 mg dose to achieve target cholesterol levels without the need for up-titration
AstraZeneca Crestor, Exanta Promotions Will Focus On Dosing Advantages
One of AstraZeneca's promotional messages for its statin Crestor (rosuvastatin) will likely focus on the ability of the 10 mg dose to achieve target cholesterol levels without the need for up-titration
AstraZeneca Launches Crestor In Canada At 15% Discount To Lipitor
AstraZeneca is launching its lipid lowering drug Crestor in Canada at a 15% discount to Pfizer's Lipitor